Free Trial
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$33.23 +0.51 (+1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$33.21 -0.02 (-0.06%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Key Stats

Today's Range
$32.48
$33.34
50-Day Range
$26.88
$33.62
52-Week Range
$22.66
$55.74
Volume
339,734 shs
Average Volume
569,720 shs
Market Capitalization
$1.53 billion
P/E Ratio
66.46
Dividend Yield
N/A
Price Target
$46.71
Consensus Rating
Moderate Buy

Company Overview

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 60% of companies evaluated by MarketBeat, and ranked 424th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omnicell has only been the subject of 2 research reports in the past 90 days.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 66.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 66.46, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.55.

  • Price to Earnings Growth Ratio

    Omnicell has a PEG Ratio of 7.23. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Omnicell's valuation and earnings.
  • Percentage of Shares Shorted

    4.56% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently increased by 6.81%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.56% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently increased by 6.81%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Omnicell has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Omnicell this week, compared to 7 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.52% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OMCL Stock News Headlines

Omnicell names Baird Radford CFO
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Omnicell Appoints New CFO Baird Radford
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $44.52 on January 1st, 2025. Since then, OMCL stock has decreased by 25.4% and is now trading at $33.23.

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Thursday, July, 31st. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell's revenue for the quarter was up 5.0% compared to the same quarter last year.
Read the conference call transcript
.

Omnicell subsidiaries include these companies: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and more.

Top institutional investors of Omnicell include Lazard Asset Management LLC (3.72%), Sumitomo Mitsui Trust Group Inc. (3.04%), Geode Capital Management LLC (2.55%) and Qube Research & Technologies Ltd (1.42%). Insiders that own company stock include Randall A Lipps, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon.
View institutional ownership trends
.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/31/2025
Today
8/27/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
CIK
926326
Employees
3,670
Year Founded
1992

Price Target and Rating

High Price Target
$64.00
Low Price Target
$34.00
Potential Upside/Downside
+40.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.50
Trailing P/E Ratio
66.46
Forward P/E Ratio
30.49
P/E Growth
7.23
Net Income
$12.53 million
Net Margins
2.01%
Pretax Margin
3.14%
Return on Equity
4.27%
Return on Assets
2.44%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.42
Quick Ratio
1.24

Sales & Book Value

Annual Sales
$1.15 billion
Price / Sales
1.33
Cash Flow
$3.07 per share
Price / Cash Flow
10.81
Book Value
$27.51 per share
Price / Book
1.21

Miscellaneous

Outstanding Shares
45,934,000
Free Float
44,776,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
0.78

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners